基础医学与临床 ›› 2013, Vol. 33 ›› Issue (12): 1638-1641.

• 短篇综述 • 上一篇    下一篇

肿瘤抗药性的表观遗传学调控机制

许力凡,张记,田志强,吴玉章   

  1. 第三军医大学
  • 收稿日期:2013-01-21 修回日期:2013-03-25 出版日期:2013-12-05 发布日期:2013-11-28
  • 通讯作者: 吴玉章 E-mail:Wuyuzhang@yahoo.com
  • 基金资助:
    长江学者和创新团队发展计划资助

Epigenetics in cancer drug-resistance

  • Received:2013-01-21 Revised:2013-03-25 Online:2013-12-05 Published:2013-11-28

摘要: 抗肿瘤药物是目前治疗肿瘤最主要的方法,但肿瘤对药物的反应往往很短暂,且不可避免的出现抗药,使其成为攻克肿瘤最大的难题之一。目前对于肿瘤抗药的分子机制并不十分清楚,除了传统观点强调的基因突变,近年来越来越多的研究揭示了表观遗传学调控在肿瘤抗药中的作用,深入分析表观修饰对药物抗性的影响,不仅可以为肿瘤对药物的反应提供敏感的早期检测,更为肿瘤个体化治疗提供更有效的治疗靶点。

关键词: 表观遗传学, 抗肿瘤药物, 肿瘤耐药

Abstract: Anti-tumor drug remains the primary treatment for most disseminated cancers. However, the response to anti-tumor drug is often transient, and development of resistance is one of the most significant obstacles to effective cancer therapy. The molecular mechanisms underlying cancer resistance are only partially understood. In addition to genetic changes, reversible transcriptional states controlled by epigenetic are believed to play a role in generating dynamic drug-resistance. These observations have important clinical consequences as they provide an opportunity for exploring a more efficient epigenetic therapy as well as potential biomarkers mediating non-invasive monitoring.

Key words: epigenetics, anti-tumor drug, drug resistance

中图分类号: